Marie‐Laure Casadebaig

Estimands for overall survival in clinical trials with treatment switching in oncology

Juliane Manitz, Natalia Kan‐Dobrosky, Hannes Buchner et al. · Pharmaceutical Statistics · 2021 · 31 citations

Medicine, Oncology, Clinical Trial Regulation +11

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, Jesús G. Berdeja, Anna Truppel-Hartmann et al. · Blood · 2020 · 21 citations

Medicine, Hematology, Oncology +17

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Catherine Thiéblemont, Susannah Howlett, Olivier Casasnovas et al. · British Journal of Haematology · 2019 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil et al. · International Journal of Hematology · 2021 · 19 citations

Medicine, Pharmacotherapy, Chemotherapy +5

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Carla Casulo, Armando Santoro, Kiyoshi Ando et al. · Blood · 2019 · 17 citations

Pharmacy, Hematology, Pharmacotherapy +17